Sievi Capital Oyj
26.2.2021 10:31:38 CET | Globenewswire | Press release
Sievi Capital Plc
Stock exchange release 26 February 2021 at 11:30 am EET
Sievi Capital Plc - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Peura, Markus
Position: Chief Financial Officer
Issuer: Sievi Capital Plc
LEI: 743700F6CLX8JMYDEP21
Notification type: INITIAL NOTIFICATION
Reference number: 743700F6CLX8JMYDEP21_20210226102657_2
____________________________________________
Transaction date: 2021-02-25
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009008924
Nature of the transaction: ACQUISITION
Transaction details
(1): Volume: 25,805 Unit price: 1.21 EUR
(2): Volume: 1,775 Unit price: 1.21 EUR
(3): Volume: 5,020 Unit price: 1.21 EUR
Aggregated transactions
(3): Volume: 32,600 Volume weighted average price: 1.21 EUR
SIEVI CAPITAL PLC
FURTHER INFORMATION
CEO Päivi Marttila, tel. +358 400 285 358
DISTRIBUTION
Nasdaq Helsinki Ltd
Main media
www.sievicapital.fi
Sievi Capital is a listed (Nasdaq Helsinki) private equity investment company that invests in small and medium-sized Finnish companies. Sievi Capital is a partner for target companies’ management and co-owners that actively supports growth, profitability and value creation.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
